3D InSight™ Antibody Penetration Assay Service

Assess penetration and immunomodulatory efficacy of biologicals and ADCs using advanced 3D tumor models.

  • Test kinetics of antibody/ADC penetration and distribution into scaffold-free 3D tumor microtissues
  • Utilize immunhistochemical detection techniques and biomimetic tumor model with native-like ECM and tissue density  
  • Receive model suitability assessment, detection method detail, and penetration kinetic report
  • Compare multiple constructs (e.g., full-length IgG, IgG Fc, sFv, bi-specific) to determine optimal targeting and efficacy 

Model System Employed

3D InSight™ Tumor Microtissues 

learn more button no background quote



  • For pricing information and shipping costs, please request a quote, indicating the desired product, amount, and the preferred shipment date.

    Catalog # Description

    3D InSight™ Antibody Penetration Assay Service (Phase 1 – Model characterization)
    3D InSight™ Antibody Penetration Assay Service (Phase 2 – Biologic detection)
    3D InSight™ Antibody Penetration Assay Service (Phase 3 – Kinetic penetration assay)

    Please inquire for different numbers of compounds. Volume discounts for larger testing programs are available.


  • Assess penetration and immunomodulatory efficacy of biologicals and ADCs in 3D

    Penetration and distribution of biologics can depend on a variety of factors, such as tissue density, antibody affinity, antigen density per cell and physico-chemical properties. The spherical, 3D structure and more native ECM and biology of 3D InSight™ Microtissues makes them ideal for assessing penetration of antibodies and engineered antibody fragments in vitro.  Antibody penetration projects consist of three phases to determine suitability of the model system, optimize detection conditions, and then determine penetration kinetics:

    Phase 1:  assessment of model feasibility for antibody penetration assay using anti-beta integrin antibody (1 model)

    Phase 2:  optimization of detection protocol for biologic of interest by immunofluorescence (IF) (1 antibody)

    Phase 3:  assessment of antibody penetration kinetics over 3 time points (1 concentration)

    Note that all projects initiate with Phase 1, then progress to subsequent phases only upon successful completion of the previous phase.



     pic 3

    IHC images (top) of 3D InSight™ Tumor Microtissue sections stained to reveal antibody penetration (white) following 1 hour incubation with IgG Fc fragment, IgG (full-size), or control (anti-integrin) IgG. Graph (bottom) quantifying antibody penetration kinetics in μm/hour.

    pic2 pic6

    Example of time-dependent penetration of antibody into tumor microtissue. Immunohistochemical staining reveals initial antibody penetration into microtissue following 5 minute exposure (left), and more in-depth penetration following 1 hour of exposure to the antibody (right).

    Model Systems

    Exposure time

    • Varies by project


    • Histology/IF

    Data delivery

    • Feasibility report for Phase 1 assessment
    • Method description and imaging results for IF detection of target antibody
    • Penetration kinetic based on IF for target antibody and control (anti-beta integrin)

Company video